NEW YORK, Jan. 14, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Clovis Oncology, Inc. (NASDAQ:CLVS) between May 20, 2014 and November 13, 2015.
You are hereby notified that Levi & Korsinsky has commenced a securities class action lawsuit in the USDC for the District of Colorado. If you purchased or otherwise acquired Clovis Oncology securities between May 20, 2014 and November 13, 2015, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/clovis-oncology-clvs
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) the New Drug Application (“NDA”) that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates; (2) Clovis’ Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses; (3) Clovis presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses; (4) as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected; and (5) as a result of the foregoing, Clovis’ NDA was likely to be delayed and/or rejected by the FDA.
If you suffered a loss in Clovis Oncology you have until January 18, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Apple Turns 50: From Garage Startup to AI Crossroads
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
First Western Ship Transits Strait of Hormuz Since Iran War Began
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 



